contains also B-and T-cell epitopes and plays a role in diverse functions such as infectivity, viral fusion and syncytium formation [12, 13] . To develop a vaccine that is widely applicable, one must consider HIV-1 env gene variation. The principal approach to monitor diversity has been through genetic sequences, however, sequencing is expensive and laborious and therefore its use is limited. An alternative approach is serotyping which can be used to screen large population groups. Previous studies [14-161 on binding of serum fiom HIV-1-infected individuals to peptides, representing the highly antigenic HIV-1 neutralization epitope of the V3 loop of known sequences from diverse isolates, have shown this method to be relevant in studying antigenic and genetic diversity of HIV-1 [14-161. This technique has also been used to provide epidemiologic information about the dynamics of the spread of some virus types in certain geographic areas [17] . We used this serologic approach mainly to study the spread of the two chimpanzee lentiviruses and one of the most aberrant HIV-1 strains (HIV-~ANT-~O; group O) in human sera fiom different geographic regions [18-221. We compared the antibody reactions to these three divergent V3 peptides with reactions to peptides fiom known North American and Zaïrean strains.
Materials and methods

Patients and sera
A total 2495 sera plositive for HIV-1 antibodies were collected and stored at 20°C. The sera had been screened for HIV antibodies at the time of collection with a commercial enzyme-linked immunosorbent assay (ELISA) kit, and positive samples were confirmed with a commercial Western blot (WB) or a recombinant proteidsynthetic peptide line immunoassay (INNOLIA HIV-1+2, Innogenetics, Ghent, Belgium). Serum samples were collected fiom symptomatic and asymptomatic individuals in nine different countries: Brazil (n =163, 1989 Brazil (n =163, -1991 , Belgium (n =379, 1989 Belgium (n =379, -1992 , Côte d'Ivoire (n =380, 1990 , Niger (n=99, 199&1991), Cameroon (n=185, 1991 , Gabon (n=188, 1989 Gabon (n=188, -1992 , Zdire (n =418,1990 Zdire (n =418, -1991 , Kenya (n 409,1991 Kenya (n 409, -1992 and Rwanda (n=574, 1988 Rwanda (n=574, -1990 .
Peptides
The synthetic peptides were synthesized by Neosystems, Strasbourgh, France. The amino-acid sequences of the peptides are shown in Table 1 .
Peptide assay
Antibodies to the V3 loop peptides were tested by ELISA. Stock solutions (1 mg/ml) of each peptide were reconstituted in 0.05 mol/l carbonate buffer (pH 9.6) and stored at 20°C. One hundred nanograms of peptides in 200 pl carbonate buffer were coated overnight at room temperature into each well of microtitre plates (NUNC, immunoplate, Copenhagen, Denmark). The plates were washed twice with wash solution [phosphate buffer solution (PBS), 0.01%) merthiolate, 0.05% Tween 201 before use. Non-specific binding sites were blocked by incubation with 200pl PBS containing 0.05% Tween 20 and 2% bovine serum albumin (BSA) at 37°C for 2 h. Serum dilutions (1/200) were made in blocking buffer and 200 p1 w a s incubated with the immobilized peptides for 1 h at 37°C. After washing, antihuman immunoglobulin G peroxidase conjugate in blocking buffer was added and incubated for 1 h at 37°C. After washing, bound antibodies were visualized by adding substrate [8.7mg tetramethylbenzidine/ml dimethylsulphoxide (DMSO) diluted 1/100 in 0.1 mol/l citrate phosphate buffer, pH 4.3 and 0.006%) H20.1. The reaction was stopped by adding 50 pl sulphuric acid and the optical densities (OD) were read at 450nm. Ten negative sera from the corresponding country were used to establish the cut-off value of each assay, which was the mean of the OD of the negative sera plus three SD. Cutoff values calculated in this manner ranged &om 0.15 to 0.5. For uniformity and to eliminate non-specific reactivity the highest cut-off value (0.5) was used for all the assays [15, 22] .
Western blot (WB)
WB were prepared from the H I V -~A N T -~~ and the sIv,p,-,b viruses as described previously [21] . 
Results prevalences of antibodies to the different peptides
The prevalences of antibody reaction to different V3 peptides in the different countries are summarized in Table 2 . In each country the highest antibody reaction was observed against the HIV-1 MN peptide (subtype B), although prevalences were different and ranged from 91.7 to 58.8%, with the lowest prevalence in Brazil. The second most recognised peptide was SF2, also belonging to subtype B. Antibody binding to the two other peptides from the same B subtype (HXE32 and RF) were low overall in all countries.
Prevalence rates of antibodies to the peptides derived fiom Zairean strains belonging to subtype D were generally lower. Antibodies to this subtype were almost absent in sera from Brazil, and the O D were low (OD < 1.5 or OD/cut-off ratio < 3).
Relative high prevalences were seen for the V3 loop peptides derived from the chimpanzee lentiviruses, especially for the peptide from the SIVcpz-gb strain, isolated from a chimpanzee in Gabon. The lowest rates were seen in Brazil (4.2%) and Belgium (25.7%). Among the Afiican countries, the highest prevalences were observed in West Africa and the lowest in the East Afiican country of Kenya (Table 2 ). Prevalences to the V3 loop derived from the SIVcpz-a,lt strain were much lower. Most of the sera (YlN) reacting with the SIVcp,-ant peptide reacted simultaneously with the sIv,-p,-,b peptide; the remainder (9%) had only weak antibody reactions to the SIVcpane peptide.
Prevalences of sera reactive to the V3 loop peptide derived &om the aberrant strain HIV~ANTJO, from Cameroon, were very low. The highest rates were observed in Cameroon (10.2%). Nieer (6%) and Gabon
Simultaneous antibody response to various peptides and to different subtypes
As can be seen from the data on the prevalences to each individual peptide (Table 2) , the majority of the sera reacted with more than one peptide. The amount of sera reacting simultaneously with different peptides varies for each country (data not shown).
Among the 2495 sera tested, 2439 were analysed further for the possible combinations of antibody patterns to the three major subtypes (subtypes B and D, and SIVcPz). Sera reactive with one or more V3 peptides of HIV-1 isolates from subtype B were observed most frequently (31.8%).
Overall, 1007 sera (41.394) had antibodies to the peptides &om subtype D, among which 22 reacted only with these peptides. AU others also showed a reaction to one or more peptides from subtype B. Of all the sera tested, Y05 (37.1%) out of 2439 reacted with at least one of the two SIV,,, peptides. Among these, 319 (35.2%) reacted simultaneously with subtype B peptides, only 23 (2.5%) with subtype D and 524 (57.Y%) with both. Thirty-nine sera reacted only with SIV,,, peptides.
Antibody reaction to HIV-lANT-,O peptide in combination with other genetic subtypes
On the 2495 sera tested, 81 (3.2%) had antibodies to the H 1 v -1~~~7 0 peptide. We subdivided these sera into three groups according to OD and examined the number of simultaneous reactions with other peptides. The majority of the sera (61 out of 81) reacting with ANT-70 had low antibody reactions (OD < 1.5); only six (YS%) of these reacted with the HIV-~ANT-~O peptide only or in combination with one subtype only, versus five (55.5%) out of nine, and nine (81.8%)) out of 11 in the groups with intermediate (1.5 < OD < 2.5) and high (OD > 2.5) antibody response, respectively. A high OD with the H I V -~A N T -~O peptide indicates a more specific reaction.
-(4.6%). Reactions witd high ÖD (52.5) were only seen in Cameroon and Gabon, two neighbouring countries, where reactions were very specific to this peptide.
Relation between antibody response to HIV-1 A N T J~ and SIVcpz-gab peptides and gpl20 antibodies on WB Thirty-six sera with antibodies to the H I V -~A N T -~~ peptide and eight sera with antibodies to the SIv,-,,&, peptide only were tested on in-house WB strips from the corresponding viruses. The sera were subdivided in different categories according to their OD. All eight sera with OD > 2.5 had antibodies to the whole gp120 of the H 1 v -1~~~~7 0 virus on WB, versus three out of six sera with OD be.tween 1.5 and 2.49, and three out of 16 sera with OD between 0.5 and 1.49. These three sera had antibodies to H I V -~A N T -~~ peptide ody. None of the six sera without antibodies to the H I V -~A N T -~~ peptide reacted with the gp120 (Table 3) . One of the eight sera with antibodies to the SIVcpz-$, peptide only and with OD > 2.5 showed a weak antibody reaction to the a 1 2 0 protein of the corresponding virus on WB.
subtype B were generally lower as observed in previous studies [14, 23] . Prevalences of antibodies to V3 peptides derived from Zaïrean strains belonging to subtype D were generally lower than to subtype B. The highest reactivities were observed in sera &om Africa, although no significant differences were observed between East, Central and West African countries. Interestingly, antibodies to these peptides are almost always associated with antibodies to subSurprisingly, high amounts of sera had antibodies to the peptides derived from the chimpanzee lentiviruses, especially to the sIV,p,-,b v3 peptide. In analogy to the subtype D peptides very low reactions were seen in Brazil. For the Belgian sera a link with Africa or Afi-icans was documented (data not shown), also indicating that these are peptides with an African origin. This was also the case for reaction with subtype D peptides in Belgian sera. Onlv 3% of sera reacted with the H I V -~A N T -~~ peptype B. the HIV-~ANTJO peptide only. This peptide seemed tions to the A N T 7 0 V 3 peptide in enzyme-linked immunosorbent to be more specific than the others tested, especially assay (ELISA) in the different countries.
when high OD were observed. From our results, this virus seemed to be located in two neighbouring Central
A f i i c a n countries, Gabon and Cameroon, and confirms in ELISA tested Western blot data of a previous preliminary study [36] . In support of our findings, a new HIV-1~~~-70-like virus (MVP51SO) OD22.5 has been recently isolated from a Cameroonian HIV- Overall, about 10% of the HIV-antibody-positive sera tested had no antibodies to any öf the 10 V3 peptides, In each the highest prevalences were observed HIV-1 isolates belonging to different subtypes helps to against the HIV-lMN peptide, to s u b w e B. The prevalence of 88*8% in Belgian Sera is comparable rapidly document the existence of different V3 peptide reactivity patterns in different geographical localities. with the 79-1000/;; observed in the United States and As described previously for East Afiican countries [14, 25] , our study showed that in West and Central African countries the prevalences to the H 1 v -l~~ peptide were high. Seroreactivity to other peptides from The extent to which these patterns reflect the circulation of different HIV-1 strains in a particular population is not yet clear due to the simultaneous reactions with peptides from different strains and subtypes. The relevance of human sera containing antibodies reactive to the SIV,,, peptides in ELISA needs to be fùrther Europe [14,23-251. clarified by sequence data. The large number of sera that reacted simultaneously with other peptides indicate that these are more likely to be crossreactions than specific antibody responses. On the other hand, reactions with the HIV-lANT-70 peptide are more specific and serology using the v3 peptide of HIV-~ANT-~O can increase the chance of finding viruses belonging to subtype O in a particular population. Studying the spread of HIV-1 viruses fiom group O is important since some of their sera react negatively in Some HIV-screening assays and produce indeterminate WEi patterns [32]. Studying the spread of these viruses will give an indication as to whether the present guidelines and strategies for .blood screening and serodiagnosis need modification.
